News | April 29, 2013

Simple Home Test Can Halve the Risk of Stroke for Patients on Warfarin

UK Blood Clots Teststing Wafarin Self Monitoring

April 29, 2013 — A simple self-monitoring test could reduce the risk of stroke by half in thousands of people in the United Kingdom who currently take warfarin to prevent blood clots. Better access to self-monitoring of international normalized ratio (INR) levels, which measures how long it takes blood to form a clot, could also lower mortality rates by nearly two fifths,[1] reduce the number of complications and has the potential to save the U.K. National Health Service (NHS) around £62 million a year,[2] a group of members of  parliament (MPs), patients and charities stated this week.

Speaking in Parliament, Virendra Sharma, MP and member of the Health Select Committee, said that many patients who take the anticoagulant warfarin were not benefitting from self-monitoring through either a lack of awareness or issues around access. He stated that "There are more than 1.2 million people in the U.K. on warfarin[3,4] but fewer than 2 percent of them benefit from self-monitoring."[5]

He went on to say: "If more patients are able to choose to self-monitor, it would improve the quality of their care and create savings for the NHS. We need to see more opportunities for people to discuss the option of self-monitoring with their GP. So today we are encouraging patients and their families to write to their local MPs asking for self-monitoring technology to be made available on NHS prescription and to register their support for the ACSMA campaign atwww.acsma.org.uk."

Warfarin is used to reduce the risk of blood clots in conditions such as atrial fibrillation, deep vein thrombosis, pulmonary embolism and in people with mechanical heart valves.

This week at the House of Commons, the AntiCoagulation Self-Monitoring Alliance (ACSMA) launched a new campaign to increase patient access via prescription to self-monitoring technology for those on longterm warfarin treatment. ACSMA comprises four of the U.K.'s leading charities and patient groups — AntiCoagulation Europe (ACE); the Children's Heart Federation; the Atrial Fibrillation Association (AF Association) and; the For Mechanical Heart Valve Support Group. Healthcare company Roche is also part of the alliance.

References:

1. Heneghan C, et al. "Self-monitoring of oral anticoagulation: a systematic review and meta-analysis." Lancet 2006; 367(9508): 404-11.

2. Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, et al. "Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling [online]." Health Technol. Assess. 2007 Oct; 11(38): iii-iv, ix-66.

3. Gardiner, et al. "Patient self-testing is a reliable and acceptable alternative to laboratory monitoring." Br J Haem 2004; 128: 242-47.

4. Office for National Statistics 2008. Accessed 16 June 2011.

5. Data on file

Related Content

Icosapent Ethyl (Vascepa) significantly Reduces Revascularizations in Statin Patients in the REDUCE-IT REVASC analyses presented as a late-breaking study at SCAI 2020. Photo by Dave Fornell

Icosapent Ethyl (Vascepa) significantly reduces revascularizations in statin patients based on data from the REDUCE-IT REVASC analyses, presented as a late-breaking study at SCAI 2020. Photo by Dave Fornell

News | Pharmaceuticals | May 17, 2020
May 17, 2020 – Patients with high lipid levels have an increased risk for ischemic events, despite statin therapy.
Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial. #ACC20 #ACC2020

Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial.

News | Pharmaceuticals | March 28, 2020 | Dave Fornell, Editor
March 28.
The U.S. Food and Drug Administration (FDA) approved Esperion's bempedoic acid (Nexletor) tablet, an oral, once-daily, non-statin low-density lipoprotein cholesterol (LDL-C) lowering medicine. The drug is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. 
Feature | Pharmaceuticals | February 24, 2020
February 24, 2020 — The U.S.
This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.

This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.

News | Pharmaceuticals | January 09, 2020
January 9, 2020 – Researchers may have discovered a way to turn back the clock on aging heart muscles in fruit flies,
 Christie Ballantyne

Dr. Christie Ballantyne, professor of medicine and chief of the section of cardiology at Baylor College of Medicine

News | Pharmaceuticals | December 30, 2019
December 30, 2019 — A drug therapy targeting the production of a protein produced by the liver has led to sustained a
Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.
Feature | Pharmaceuticals | December 16, 2019 | Dave Fornell, Editor
The U.S. Food and Drug Administration (FDA) approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive...
Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after biologic therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after psoriasis biologic drug therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

 

Feature | Pharmaceuticals | July 31, 2019
July 31, 2019 — Researchers found anti-inflammatory drug therapies used to treat moderate to severe psoriasis can sig
Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...